Ingenol mebutate (IM) has recently been approved for the topical treatment of actinic keratoses. It appears to have a dual mechanism of action: rapid necrosis after gel application and a subsequent immune-mediated response, which targets any residual dysplastic epidermal cells. We report the successful treatment of a woman, who had been relapsing into Bowen's disease (BD) on her right forefinger for 8 years. During her clinical history, she had received an allogeneic, HLA-identical stem cell transplant for myeloproliferative syndrome with a JAK2V617F mutation and lobectomy of the pulmonary right lower lobe for adenocarcinoma. We used dermoscopy to monitor the therapeutic response of BD. We discuss IM gel as a possible therapeutic option for BD.

Keywords:
Ingenol mebutate, Bowen’s disease, Dermoscopy, Non-melanoma skin cancers
1.
Cox NH, Eedy DJ, Morton CA; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists: Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol 2007;156:11-21.
2.
Morton CA, Birnie AJ, Eedy DJ: British association of dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014. Br J Dermatol 2014;170:245-260.
3.
Zalaudek I, Argenziano G, Leinweber B, Citarella L, Hofmann-Wellenhof R, Malvehy J, Puig S, Pizzichetta MA, Thomas L, Soyer HP, Kerl H: Dermoscopy of Bowen's disease. Br J Dermatol 2004;150:1112-1116.
4.
Mun JH, Park JM, Song M, Jwa SW, Kim HS, Ko HC, Kim BS, Kim MB: The use of dermatoscopy to monitor therapeutic response of Bowen disease: a dermatoscopic pathological study. Br J Dermatol 2012;167:1382-1385.
5.
Hofbauer G, Anliker M, Boehncke WH, Brand C, Braun R, Gaide O, Hafner J, Hunger R, Itin P, Kaeuper G, Lautenschlager S, Mainetti C, Streit M: Swiss clinical practice guidelines on field cancerization of the skin. Swiss Med Wkly 2014;144:w14026.
6.
Rosen RH, Gupta AK, Tyring SK: Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 2012;66:486-493.
7.
Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B: Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012;366:1010-1019.
8.
Morley GL, Matthews JH, Verpetinske I, Thom GA: A comparative study examining the management of Bowen's disease in the United Kingdom and Australia. Dermatol Res Pract 2015;2015:421460.
9.
Micali G, Lacarrubba F, Nasca MR, Ferraro S, Schwartz RA: Topical pharmacotherapy for skin cancer: part II. Clinical applications. J Am Acad Dermatol 2014;70:979.e1-e12.
10.
Argenziano G, Zalaudek I, Corona R, Sera F, Cicale L, Petrillo G, Ruocco E, Hofmann-Wellenhof R, Soyer HP: Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004;140:1485-1489.
11.
Zalaudek I, Di Stefani A, Argenziano G: The specific dermoscopic criteria of Bowen's disease. J Eur Acad Dermatol Venereol 2006;20:361-362.
12.
Payapvipapong K, Tanaka M: Corona of glomerular vessels: a diagnostic marker of hyperkeratotic Bowen's disease. Dermatol Surg 2013;39:1395-1398.
13.
Zalaudek I, Argenziano G: Dermoscopy of actinic keratosis, intraepidermal carcinoma and squamous cell carcinoma. Curr Probl Dermatol 2015;46:70-76.
14.
Ogbourne SM, Suhrbier A, Jones B, Cozzi SJ, Boyle GM, Morris M, McAlpine D, Johns J, Scott TM, Sutherland KP, Gardner JM, Le TT, Lenarczyk A, Aylward JH, Parsons PG: Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833-2839.
15.
Cozzi SJ, Ogbourne SM, James C, Rebel HG, de Gruijl FR, Ferguson B, Gardner J, Lee TT, Larcher T, Suhrbier A: Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol 2012;132:1263-1271.
16.
Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF: Ingenol mebutate signals via PKC/MEK/ERK in keratinocytes and induces interleukin decoy receptors IL1R2 and IL13RA2. Mol Cancer Ther 2015;14:2132-2142.
17.
Longo C, Borsari S, Benati E, Moscarella E, Alfano R, Argenziano G: Dermoscopy and reflectance confocal microscopy for monitoring the treatment of actinic keratosis with ingenol mebutate gel: report of two cases. Dermatol Ther (Heidelb) 2016;6:81-87.
18.
Braun SA, Homey B, Gerber PA: [Successful treatment of Bowen disease with ingenol mebutate]. Hautarzt 2014;65:848-850.
19.
Lee JH, Lee JH, Bae JM, Kim GM: Successful treatment of Bowen's disease with ingenol mebutate 0.05% gel. J Dermatol 2015;42:920-921.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.